These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 30554920)

  • 1. A Contraction Stress Model of Hypertrophic Cardiomyopathy due to Sarcomere Mutations.
    Cohn R; Thakar K; Lowe A; Ladha FA; Pettinato AM; Romano R; Meredith E; Chen YS; Atamanuk K; Huey BD; Hinson JT
    Stem Cell Reports; 2019 Jan; 12(1):71-83. PubMed ID: 30554920
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Myosin Sequestration Regulates Sarcomere Function, Cardiomyocyte Energetics, and Metabolism, Informing the Pathogenesis of Hypertrophic Cardiomyopathy.
    Toepfer CN; Garfinkel AC; Venturini G; Wakimoto H; Repetti G; Alamo L; Sharma A; Agarwal R; Ewoldt JK; Cloonan P; Letendre J; Lun M; Olivotto I; Colan S; Ashley E; Jacoby D; Michels M; Redwood CS; Watkins HC; Day SM; Staples JF; Padrón R; Chopra A; Ho CY; Chen CS; Pereira AC; Seidman JG; Seidman CE
    Circulation; 2020 Mar; 141(10):828-842. PubMed ID: 31983222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations.
    Witjas-Paalberends ER; Güçlü A; Germans T; Knaapen P; Harms HJ; Vermeer AM; Christiaans I; Wilde AA; Dos Remedios C; Lammertsma AA; van Rossum AC; Stienen GJ; van Slegtenhorst M; Schinkel AF; Michels M; Ho CY; Poggesi C; van der Velden J
    Cardiovasc Res; 2014 Jul; 103(2):248-57. PubMed ID: 24835277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modelling diastolic dysfunction in induced pluripotent stem cell-derived cardiomyocytes from hypertrophic cardiomyopathy patients.
    Wu H; Yang H; Rhee JW; Zhang JZ; Lam CK; Sallam K; Chang ACY; Ma N; Lee J; Zhang H; Blau HM; Bers DM; Wu JC
    Eur Heart J; 2019 Dec; 40(45):3685-3695. PubMed ID: 31219556
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation-specific pathology and treatment of hypertrophic cardiomyopathy in patients, mouse models and human engineered heart tissue.
    Wijnker PJM; van der Velden J
    Biochim Biophys Acta Mol Basis Dis; 2020 Aug; 1866(8):165774. PubMed ID: 32217077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isogenic models of hypertrophic cardiomyopathy unveil differential phenotypes and mechanism-driven therapeutics.
    Bhagwan JR; Mosqueira D; Chairez-Cantu K; Mannhardt I; Bodbin SE; Bakar M; Smith JGW; Denning C
    J Mol Cell Cardiol; 2020 Aug; 145():43-53. PubMed ID: 32531470
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced myofilament calcium sensitivity aggravates abnormal calcium handling and diastolic dysfunction in patient-specific induced pluripotent stem cell-derived cardiomyocytes with MYH7 mutation.
    Guo G; Wang L; Li X; Fu W; Cao J; Zhang J; Liu Y; Liu M; Wang M; Zhao G; Zhao X; Zhou Y; Niu S; Liu G; Zhang Y; Dong J; Tao H; Zhao X
    Cell Calcium; 2024 Jan; 117():102822. PubMed ID: 38101154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibiting cardiac myeloperoxidase alleviates the relaxation defect in hypertrophic cardiomyocytes.
    Ramachandra CJA; Kp MMJ; Chua J; Hernandez-Resendiz S; Liehn EA; Knöll R; Gan LM; Michaëlsson E; Jonsson MKB; Ryden-Markinhuhta K; Bhat RV; Fritsche-Danielson R; Lin YH; Sadayappan S; Tang HC; Wong P; Shim W; Hausenloy DJ
    Cardiovasc Res; 2022 Jan; 118(2):517-530. PubMed ID: 33705529
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The myosin mesa and the basis of hypercontractility caused by hypertrophic cardiomyopathy mutations.
    Nag S; Trivedi DV; Sarkar SS; Adhikari AS; Sunitha MS; Sutton S; Ruppel KM; Spudich JA
    Nat Struct Mol Biol; 2017 Jun; 24(6):525-533. PubMed ID: 28481356
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Myosin inhibitor reverses hypertrophic cardiomyopathy in genotypically diverse pediatric iPSC-cardiomyocytes to mirror variant correction.
    Kinnear C; Said A; Meng G; Zhao Y; Wang EY; Rafatian N; Parmar N; Wei W; Billia F; Simmons CA; Radisic M; Ellis J; Mital S
    Cell Rep Med; 2024 May; 5(5):101520. PubMed ID: 38642550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypertrophic Cardiomyopathy: Diverse Pathophysiology Revealed by Genetic Research, Toward Future Therapy.
    Hayashi T
    Keio J Med; 2020 Dec; 69(4):77-87. PubMed ID: 32224552
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies.
    Yotti R; Seidman CE; Seidman JG
    Annu Rev Genomics Hum Genet; 2019 Aug; 20():129-153. PubMed ID: 30978303
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spectrum of Mutations in Hypertrophic Cardiomyopathy Genes Among Tunisian Patients.
    Jaafar N; Gómez J; Kammoun I; Zairi I; Amara WB; Kachboura S; Kraiem S; Hammami M; Iglesias S; Alonso B; Coto E
    Genet Test Mol Biomarkers; 2016 Nov; 20(11):674-679. PubMed ID: 27574918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Perturbed length-dependent activation in human hypertrophic cardiomyopathy with missense sarcomeric gene mutations.
    Sequeira V; Wijnker PJ; Nijenkamp LL; Kuster DW; Najafi A; Witjas-Paalberends ER; Regan JA; Boontje N; Ten Cate FJ; Germans T; Carrier L; Sadayappan S; van Slegtenhorst MA; Zaremba R; Foster DB; Murphy AM; Poggesi C; Dos Remedios C; Stienen GJ; Ho CY; Michels M; van der Velden J
    Circ Res; 2013 May; 112(11):1491-505. PubMed ID: 23508784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cardiomyocyte Apoptosis Is Associated with Contractile Dysfunction in Stem Cell Model of
    Loiben AM; Chien WM; Friedman CE; Chao LS; Weber G; Goldstein A; Sniadecki NJ; Murry CE; Yang KC
    Int J Mol Sci; 2023 Mar; 24(5):. PubMed ID: 36902340
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Studying Pathogenetic Contribution of a Variant of Unknown Significance, p.M659I (c.1977G > A) in MYH7, to the Development of Hypertrophic Cardiomyopathy Using CRISPR/Cas9-Engineered Isogenic Induced Pluripotent Stem Cells.
    Pavlova SV; Shulgina AE; Zakian SM; Dementyeva EV
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Faster cross-bridge detachment and increased tension cost in human hypertrophic cardiomyopathy with the R403Q MYH7 mutation.
    Witjas-Paalberends ER; Ferrara C; Scellini B; Piroddi N; Montag J; Tesi C; Stienen GJ; Michels M; Ho CY; Kraft T; Poggesi C; van der Velden J
    J Physiol; 2014 Aug; 592(15):3257-72. PubMed ID: 24928957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lifelong Clinical Impact of the Presence of Sarcomere Gene Mutation in Japanese Patients With Hypertrophic Cardiomyopathy.
    Nakashima Y; Kubo T; Sugiura K; Ochi Y; Takahashi A; Baba Y; Hirota T; Yamasaki N; Kimura A; Doi YL; Kitaoka H
    Circ J; 2020 Sep; 84(10):1846-1853. PubMed ID: 32830170
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Study familial hypertrophic cardiomyopathy using patient-specific induced pluripotent stem cells.
    Han L; Li Y; Tchao J; Kaplan AD; Lin B; Li Y; Mich-Basso J; Lis A; Hassan N; London B; Bett GC; Tobita K; Rasmusson RL; Yang L
    Cardiovasc Res; 2014 Nov; 104(2):258-69. PubMed ID: 25209314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incomplete-penetrant hypertrophic cardiomyopathy
    Lee S; Vander Roest AS; Blair CA; Kao K; Bremner SB; Childers MC; Pathak D; Heinrich P; Lee D; Chirikian O; Mohran SE; Roberts B; Smith JE; Jahng JW; Paik DT; Wu JC; Gunawardane RN; Ruppel KM; Mack DL; Pruitt BL; Regnier M; Wu SM; Spudich JA; Bernstein D
    Proc Natl Acad Sci U S A; 2024 May; 121(19):e2318413121. PubMed ID: 38683993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.